Sandoz Ups Biosimilar Game With Alteogen Subcutaneous Tech Deal

Alteogen Comments Suggests Deal Worth Up To $145m

 
• By Dean Rudge
  
Alliance
Alteogen is also developing a biosimilar eylea product • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products